Journal Logo

CLINICAL, PARACLINICAL CHARACTERISTICS AND OUTCOME IN ALGERIAN MYELODYSPLASTIC SYNDROMES: A SINGLE CENTER EXPERIENCE

PB2093

Talbi, T. F.1; abbadi, M. R.1; menouer, S.2; belakhel, S.1; djouadi, K.1; ardjoun, F. Z.1

doi: 10.1097/01.HS9.0000566856.38756.67
Publication Only: Myelodysplastic syndromes - Clinical
Free

1hematology, military hospital, algeria

2hematology, military hospital, algiers, Algeria

Back to Top | Article Outline

Background:

Myelodysplastic syndromes refer to a heterogeneous group of clonal diseases affecting the hematopoietic stem cell resulting in qualitative and quantitative abnormalities of the three myeloid lineages. The overall incidence is 03-05/105 hbts/year without ethnic difference; it increases with age (03-15/105 hbts/year between 50-70 years and 15-50/105 hbts/year> 70 years).

Back to Top | Article Outline

Aims:

we analyzed the characteristics of our patients and we investigated the impact of prognostic factors and parculier comorbidities on their future

Back to Top | Article Outline

Methods

a single-center descriptive retrospective study, including all MDS diagnosed in the hematology department of military hospital over a 21-year period (1994-2014) from patient records. The diagnosis is retained on blood and bone marrow cytology and Perls staining (the karyotype was carried out in a few cases) after exclusion of a vitamin deficiency (ferritin, folate, vitamin B12: dosage or therapeutic test), or associated pathology (thyroid, lever, inflammatory or haemolytic). We have classified our patients according to the WHO classification (2016).

Back to Top | Article Outline

Results:

n = 85 evaluable pts: the clinical, biological and cytological characteristics of patients are summarized in the following table I, the observed comorbidities: cardiovascular d (40%), diabetes (30%), and respiratory insufficiency (29%): more frequent (HR = 1.65, 95% CI = 0.65- 3, 66) in men/women and more severe (≥3 points: 12 patients): HR: 4.5: 95% CI: 1, 88-5) P = 0.012. Patients 65 years and older have a high prevalence of comorbidities (vs young): HCT-CI score: HR = 0, 19 (95% CI: 0, 023-0, 89): p = 0.01, with a very negative impact on survival (p = 0.001).

Figure

Figure

Back to Top | Article Outline

Summary/Conclusion:

the presentation of MDS in our series is similar to that of national and international series with a particularly poor prognosis since this pathology preferentially affects the elderly, with in most cases associated defects making the management very difficult. Immunomodulatory agents could improve the evolution of these patients.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.